Jump to main content
Jump to site search


Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain

Author affiliations

Abstract

Neuropathic pain is caused by a lesion or dysfunction in the nervous system, and it may arise from illness, be drug-induced or caused by toxin exposure. Since the discovery of two G-protein-coupled cannabinoid receptors (CB1 and CB2) nearly three decades ago, there has been a rapid expansion in our understanding of cannabinoid pharmacology. This is currently one of the most active fields of neuropharmacology, and interest has emerged in developing cannabinoids and other small molecule modulators of CB1 and CB2 as therapeutics for neuropathic pain. This short review article provides an overview of the chemotypes currently under investigation for the development of novel neuropathic pain treatments targeting CB1 receptors.

Graphical abstract: Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain

Back to tab navigation

Publication details

The article was received on 04 Dec 2018, accepted on 12 Mar 2019 and first published on 18 Mar 2019


Article type: Review Article
DOI: 10.1039/C8MD00595H
Citation: Med. Chem. Commun., 2019, Advance Article

  •   Request permissions

    Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain

    S. D. Banister, K. Krishna Kumar, V. Kumar, B. K. Kobilka and S. V. Malhotra, Med. Chem. Commun., 2019, Advance Article , DOI: 10.1039/C8MD00595H

Search articles by author

Spotlight

Advertisements